Achieve Life Sciences, Inc.
NASDAQ:ACHVBiotechnology
-$0.38 today
- Market cap
- $697.68M
- Beta
- 2.26
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$0.97
Volume 1.09M
Average 1.44M
ACHV Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Achieve Life Sciences, Inc.NASDAQ: ACHV
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $57K fell 8.1% year over year, behind the -4.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -1.1% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -8.1% toward the trailing-twelve-month pace of -4.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 228K USD
- Year-over-year change
- -0.4%
- 4-year CAGR
- -2.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 228K | -0.4% |
| FY2024 | 2024-12-31 | 229K | +0.4% |
| FY2023 | 2023-12-31 | 228K | -3.4% |
| FY2022 | 2022-12-31 | 236K | -5.6% |
| FY2021 | 2021-12-31 | 250K | — |
Depreciation & Amortization vs competitors
How ACHV compares with its peers on the latest reported figures
No competitor Depreciation & Amortization figures are available to compare.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 229K | 228K |
| Gross Profit | 0 | 0 | 0 | (229K) | (228K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.97M | 30.08M | 15.81M | 22.82M | 22.96M |
| Selling, General & Admin | 9.13M | 10.72M | 11.44M | 16.25M | 31.87M |
| Operating Expenses | 33.09M | 40.8M | 27.25M | 38.84M | 54.65M |
| Depreciation & Amortization | 250K | 236K | 228K | 229K | 228K |
| EBITDA | (32.9M) | (40.33M) | (26.73M) | (37.42M) | (53.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (33.09M) | (40.8M) | (27.25M) | (39.07M) | (54.88M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 17K | 199K | 825K | 2.36M | 1.5M |
| Interest Expense | 0 | 1.79M | 2.85M | 2.18M | 819K |
| Other Income / Expenses | (58K) | (1.55M) | (2.57M) | (758K) | 232K |
| Income Before Tax | (33.15M) | (42.35M) | (29.82M) | (39.83M) | (54.65M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (33.15M) | (42.35M) | (29.82M) | (39.83M) | (54.65M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (4.05) | (3.95) | (1.50) | (1.24) | (1.25) |
| EPS (Diluted) | (4.05) | (3.95) | (1.50) | (1.24) | (1.25) |
| Weighted Avg Shares | 8.12M | 10.59M | 19.83M | 32.07M | 43.59M |
| Weighted Avg Shares (Diluted) | 8.12M | 10.59M | 19.83M | 32.07M | 43.59M |
Achieve Life Sciences, Inc.
NASDAQ:ACHV
Intrinsic Alpha fair value
Locked
Current Price
$6.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.